Skip to main content

Advertisement

SpringerLink
Log in

Controversies in liver biopsy: Who, where, when, how, why?

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Liver biopsy continues to have a central role in the evaluation of patients with suspected liver disease. The procedure is often indicated to evaluate otherwise unexplained liver biochemical test abnormalities, but the precise degree of serum aminotransferase elevations that should prompt a liver biopsy is controversial, as is the need for liver biopsy in all patients with suspected nonalcoholic fatty liver disease and chronic hepatitis C. Standard liver biopsy is contraindicated in patients with severe coagulopathy and ascites, although the degree of coagulopathy that contraindicates a liver biopsy is controversial. A transjugular approach is an alternative in patients with coagulopathy or ascites. Controversy surrounds all the technical aspects of liver biopsy, particularly the choice of needle (cutting vs suction) and the use of ultrasound to mark or guide the biopsy site. Bleeding is the major complication of liver biopsy, with a risk of 0.3%; cutting needles are more likely to cause hemorrhage than are suction needles. Traditionally, liver biopsy has been the province of the hepatologist/ gastroenterologist. However, an increasing number of liver biopsies are performed by radiologists. The implications of this trend with respect to patient outcome, safety, and training of fellows is unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Grant A, Neuberger J: Guidelines on the use of liver biopsy in clinical practice. Gut 1999, 45(Suppl IV):IV1-IV11. Evidence-based guidelines from the British Society of Gastroenterology.

    Article  PubMed  Google Scholar 

  2. Sherlock S, Dooley J: Diseases of the Liver and Biliary System.Oxford: Blackwell Science; 2002.

    Google Scholar 

  3. Friedman LS, Martin P, Muñoz SJ: Laboratory evaluation of the patient with liver disease. In Hepatology: A Textbook of Liver Disease, edn 4. Edited by Zakim D, Boyer TD. Philadelphia:WB Saunders; 2003:661–708.

    Google Scholar 

  4. Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 2001, 344:495–500. Concise review with examples of histologic specimens. It focuses on complications of liver biopsy and alternative techniques.

    Article  PubMed  CAS  Google Scholar 

  5. Saadeh S, Cammell G, Carey WD, et al.: The role of liver biopsy in chronic hepatitis C. Hepatology 2000, 3:196–200.

    Google Scholar 

  6. Gish RG, guest ed: Current and future treatment therapies for liver disease. Clin Liver Dis 2001, 5:287-574.

    Google Scholar 

  7. Van Ness NM, Diehl AM: Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989, 111:473–478.

    PubMed  Google Scholar 

  8. Friedman LS, Dienstag JL, Watkins E, et al.: Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann Intern Med 1987, 107:137–144.

    PubMed  CAS  Google Scholar 

  9. Hay JE, Czaja AJ, Rakela J, et al.: The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989, 9:193–197.

    Article  PubMed  CAS  Google Scholar 

  10. Sorbi D, McGill DB, Thistle JL, et al.: An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 2000, 95:3206–3210.

    Article  PubMed  CAS  Google Scholar 

  11. Whitmire LF, Galambos JT, Phillips VM, et al.: Imaging guided percutaneous hepatic biopsy: diagnostic accuracy and safety. J Clin Gastroenterol 1985, 7:511–5.

    Article  PubMed  CAS  Google Scholar 

  12. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000, 342:1266–71. Review of the significance and clinical utility of liver biochemistry tests.

    Article  PubMed  CAS  Google Scholar 

  13. Bianchi L: Liver biopsy in elevated liver function tests? An old question revisited. J Hepatol 2001, 290–294.

  14. Prati D, Taioli E, Zanella S, et al.: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1–9. Survey of 6835 blood donors indicating that serum ALT levels correlate with body-mass index and suggesting that lowering the upper limit of normal of the serum ALT level will increase the sensitivity for detecting patients with chronic hepatitis C, with an acceptable decline in specificity.

    PubMed  CAS  Google Scholar 

  15. Piton A, Poyard T, Imbert-Bismut F, et al.: Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC group. Hepatology 1998, 27:1213–1219.

    Article  PubMed  CAS  Google Scholar 

  16. Kaplan MM. Alanine aminotransferase levels: What’s normal? Ann Intern Med 2002, 137:49–51.

    PubMed  Google Scholar 

  17. Ruhl C, Everhart JE: Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003, 124:71–79. This article reports on the US National Health and Nutrition Examination Survey of 5724 adults, which confirms an association between elevated serum ALT activity and body-mass index. The major determinants of this association were central adiposity, hyperleptinemia, and hyperinsulinemia.

    Article  PubMed  CAS  Google Scholar 

  18. Green RM, Flamm S: AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002, 123:1367–1384.

    Article  PubMed  CAS  Google Scholar 

  19. Pradat P, Alberti A, Poynard T, et al.: Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002, 36:973–977. Data on 864 hepatitis C RNA-positive subjects show that almost all those with an elevated ALT level have some fibrosis on liver biopsy.

    PubMed  Google Scholar 

  20. Forns X, Ampurdanes S, Llovet JM, et al.: Identification of chronic hepatitis C without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986–992.

    PubMed  Google Scholar 

  21. Afdahl NH: Diagnosis fibrosis in hepatitis: Is the pendulum swinging from biopsy to blood tests? Hepatology 2003, 37:972–974.

    Article  Google Scholar 

  22. Poynard T, McHutchinson J, Manns M, et al.: Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003, 38:481–492.

    Article  PubMed  CAS  Google Scholar 

  23. Zein CO, Angulo P, Lindor KD: When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 2003, 1:89–95.

    Article  PubMed  Google Scholar 

  24. Burak KW, Angulo P, Lindor KD: Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003, 98:1155–1158.

    Article  PubMed  Google Scholar 

  25. Sebagh M, Rifai K, F’ey C, et al.: All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003, 37:1293–1301.

    Article  PubMed  Google Scholar 

  26. Spycher C, Zimmermann A, Relchen J: The diagnostic value of liver biopsy. BMC Gastroenterol 2001, 1:12. Accessible online at http://www.biomedcentral.com/1471-230X/1/12.

    Article  Google Scholar 

  27. Ewe K: Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981, 26:388–93.

    Article  PubMed  CAS  Google Scholar 

  28. Maddrey WC: Liver biopsy: a 1990s perspective. In Liver Biopsy:Interpretation for the 1990s. Edited by Hoofnagle JH, Goodman Z. Thorofare, NJ: American Association for the Study of Liver Diseases; 1991:479–486.

    Google Scholar 

  29. McGill DB, Rakela J, Zinsmeister AR: A 21 year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990, 99:1396–1400.

    PubMed  CAS  Google Scholar 

  30. Dillon JF, Simpson KJ, Hayes PC: Liver biopsy bleeding time: an unpredictable event. J Gastroenterol Hepatol 1994, 9:269–271.

    PubMed  CAS  Google Scholar 

  31. Ahmed MM, Mutimer DJ, Elias E, et al.: A combined management protocol for patients with coagulation disorders infected with hepatitis C virus. Br J Haematol 1996, 95:383–388.

    Article  PubMed  CAS  Google Scholar 

  32. Venkataramani A, Behling C, Rond DR, et al.: Liver biopsies in adult hemophiliacs with hepatitis C: a United States center’s experience. Am J Gastroenterol 2000, 95:2374–2376.

    Article  PubMed  CAS  Google Scholar 

  33. Little AF, Ferris JV, Dodd GD, et al.: Image guided percutaneous hepatic biopsy: effect of ascites on the complication rate. Radiology 1996, 199: 79–83.

    PubMed  CAS  Google Scholar 

  34. Schipper HG, Lameris JS, van Delden OM, et al.: Percutaneous evacuation (PEVAC) of multivesicular echinococcal cysts with or without cystobiliary fistulas which contain non-drainable material: first results of a modified PAIR method. Gut 2002, 50:718–723.

    Article  PubMed  CAS  Google Scholar 

  35. Jacobs WH, Goldberg SB: Statement on out-patient percutaneous liver biopsy. Dig Dis Sci 1989, 34:322–3. These guidelines established the standard for liver biopsy as an outpatient procedure.

    Article  PubMed  CAS  Google Scholar 

  36. Knauer CM: Percutaneous biopsy of the liver as a procedure for outpatients. Gastroenterology 1978, 74:101–102.

    PubMed  CAS  Google Scholar 

  37. Janes CH, Lindor KD: Outcomes of patients hospitalised for complications after outpatient liver biopsy. Ann Intern Med 1993, 118:96–98.

    PubMed  CAS  Google Scholar 

  38. Alexander JA, Smith BJ: Midazolam sedation for percutaneous liver biopsy. Dig Dis Sci 1993, 38:2209–2211.

    Article  PubMed  CAS  Google Scholar 

  39. Ahmad M, Riley TRIII: Can one predict when ultrasound will be useful with percutaneous liver biopsy? Am J Gastroenterol 2001, 96:547–549.

    Article  PubMed  CAS  Google Scholar 

  40. Farrell RJ, Smiddy PF, Pilkington RM, et al.: Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. J Hepatol 1999, 30:580–587. This study of 166 patients with hepatitis C demonstrated that, compared with blind liver biopsy with a cutting needle, ultrasoundguided biopsy with an automated needle was associated with less pain and no reduction in diagnostic yield.

    Article  PubMed  CAS  Google Scholar 

  41. Caturelli E, Giacobbe A, Facciorusio D, et al.: Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site. Am J Gastroenterol 1996, 91:1318–1321.

    PubMed  CAS  Google Scholar 

  42. Vautier G, Scott B, Jenkins D: Liver biopsy: blind or guided? BMJ 1994, 309:1455–1456.

    PubMed  CAS  Google Scholar 

  43. Pagliaro L, Rinaldi F, Craxi A, et al.: Percutaneous blind biopsy vs. laparoscopy with guided biopsy in diagnosis of cirrhosis: a prospective, randomized trial. Dig Dis Sci 1983, 28:39–43.

    Article  PubMed  CAS  Google Scholar 

  44. Papini E, Pacella CM, Rossi Z, et al.: A randomized trial of ultrasound-guided anterior subcostal liver biopsy versus the conventional Menghini technique. J Hepatol 1991, 13:231–237.

    Article  Google Scholar 

  45. Cadranal J-F, Rufat I, Degos F, et al.: Practices of liver biopsy in France: results of a prospective nation-wide survey. Hepatology 2000, 32:477–481. In this survey of 2084 liver biopsies in France, sedation was used in 46% of patients and ultrasound guidance in 56%, but only 27% of procedures were performed on an outpatient basis.

    Article  Google Scholar 

  46. Younossi ZM, Teran JC, Ganiats TG, et al.: Ultrasound-guided liver biopsy for parenchymal liver disease: an economic analysis. Dig Dis Sci 1998, 43:46–50.

    Article  PubMed  CAS  Google Scholar 

  47. Pasha T, Gabriel S, Therneau T, et al.: Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology 1998, 27:1220–1226. This decision-analysis model shows that ultrasound-guided liver biopsy is cost-effective, with an incremental cost of $2731 to avoid one major complication.

    Article  PubMed  CAS  Google Scholar 

  48. Angtuaco TL, Lal SK, Banaad-Omiotek GD, et al.: Current liver biopsy practices for suspected parenchymal liver diseases in the United States: the evolving role of radiologists. Am J Gastroenterol 2002, 97:1468–1471.

    Article  PubMed  Google Scholar 

  49. Muir AJ, Trotter JF: A survey of current liver biopsy practice patterns. J Clin Gastroenterol 2002, 35:86–88.

    Article  PubMed  Google Scholar 

  50. Crawford AR, Lin X-Z, Crawford JM: The normal adult human liver biopsy: a quantitative reference standard. Hepatology 1998, 28:323–331.

    Article  PubMed  CAS  Google Scholar 

  51. Demetris AJ, Ruppert K: Pathologist’s perspective on liver needle biopsy size? J Hepatol 2003, 39:275–277.

    Article  PubMed  CAS  Google Scholar 

  52. Colloredo G, Guido M, Sonzogni A, Leandro G: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003, 39:239–244. The size of a liver biopsy specimen influences the grading and staging of chronic viral hepatitis. These authors also recommend a minimum length of 2 cm.

    Article  PubMed  Google Scholar 

  53. Regev A, Berho M, Jeffers LJ, et al.: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614–2618.

    Article  PubMed  Google Scholar 

  54. Rosch J, Lakin PC, Antonovic R, et al.: Transjugular approach to liver biopsy and transhepatic cholangiography. N Engl J Med 1973, 289:227–231.

    Article  PubMed  CAS  Google Scholar 

  55. McAfee JH, Keeffe EB, Lee RG, et al.: Transjugular liver biopsy. Hepatology 1992, 15:726–732.

    Article  PubMed  CAS  Google Scholar 

  56. Papatheodoridis DV, Patch D, Watkinson A, et al.: Transjugular liver biopsy in the 1990s: a 2-year audit. Aliment Pharmacol Ther 1999, 13:603–608. Of 157 transjugular liver biopsies in 145 patients, the biopsy sample was adequate for histologic diagnosis in 90%. Two major complications (capsular perforation) occurred.

    Article  PubMed  CAS  Google Scholar 

  57. Smith TP, Presson TL, Heneghan MA, Ryan JM: Transjugular biopsy of the liver in pediatric and adult patients using an 18-gauge automated core biopsy needle: a retrospective review of 410 consecutive procedures. AJR Am J Roentgenol 2003, 180:167–172.

    PubMed  Google Scholar 

  58. Lightdale CJ, Das L: Difficult liver biopsies: only for radiologists? Am J Gastroenterol 1997, 92:364–365.

    PubMed  CAS  Google Scholar 

  59. Sue M, Caldwell SH, Dickson RC, et al.: Variation between centres in technique and guidelines for liver biopsy. Liver 1996, 16:267–270.

    PubMed  CAS  Google Scholar 

  60. Gilmore IT, Burroughs A, Murray-Lyon IM, et al.: Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995, 36:437–441.

    PubMed  CAS  Google Scholar 

  61. Stotland BR, Lichtenstein GR: Liver biopsy complications and routine ultrasound. Am J Gastroenterol 1996, 91:1295–1296.

    PubMed  CAS  Google Scholar 

  62. Larson AM, Chan GC, Wartelle CF, et al.: Infection complicating percutaneous liver biopsy in liver transplant recipients. Hepatology 1997, 26:1406–1409.

    Article  PubMed  CAS  Google Scholar 

  63. Hamazaki K, Matsubara N, Mori M, et al.: Needle tract implantation of hepatocellular carcinoma after ultrasonically guided needle liver biopsy. J Hepatogastroenterol 1995, 42:601–606.

    CAS  Google Scholar 

  64. Lindner H: Hazards of percutaneous liver biopsy. Med Klin 1971, 66:924–929.

    PubMed  CAS  Google Scholar 

  65. Piccinino F, Sagnelli E, Pasquale G, et al.: Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165–173. Large survey reporting a rate of death from liver biopsy of 9 patients per 1000. All deaths resulted from intra-abdominal hemorrhage and occurred in patients with cirrhosis or malignant disease.

    Article  PubMed  CAS  Google Scholar 

  66. Tobin MV, Gilmore IT: Plugged liver biopsy in patients with impaired coagulation. Dig Dis Sci 1989, 34:13–15.

    Article  PubMed  CAS  Google Scholar 

  67. Denzer U, Helmreich-Becker I, Galle PR, Lohse AW: Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol 2003, 98:893–900.

    Article  PubMed  Google Scholar 

  68. Minuk GY, Sutherland LR, Wiseman D, et al.: Prospective study of the incidence of ultrasound-detected intrahepatic and subcapsular haematomas in patients randomized to 6 or 24 hours of bed rest after percutaneous liver biopsy. Gastroenterology 1987, 92:290–293.

    PubMed  CAS  Google Scholar 

  69. Van LeeuwenDJ: Liver biopsy: who should do it⋯nd who will show up in court? Am J Gastroenterol 2002, 97:1285–1288.

    Article  PubMed  Google Scholar 

  70. Gunneson TJ, Menon KVN, Wiesner RH, et al.: Ultrasoundassisted percutaneous liver biopsy performed by a physician assistant. Am J Gastroenterol 2002, 97:1472–1475. This study describes the feasibility of training a non-physician assistant to perform liver biopsy with bedside ultrasonography. Adequate tissue was obtained in 99.8% of 1086 consecutive biopsies, with a rate of complications requiring hospitalization of 0.6% of patients and no deaths.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Newton-Wellesley Hospital, 2014 Washington Street, 02462, Newton, MA, USA

    Lawrence S. Friedman MD

Authors
  1. Lawrence S. Friedman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friedman, L.S. Controversies in liver biopsy: Who, where, when, how, why?. Curr Gastroenterol Rep 6, 30–36 (2004). https://doi.org/10.1007/s11894-004-0023-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-004-0023-4

Keywords

Search

Navigation